Miller RE, Leary A, Scott CL, Serra V, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020 Sep 28. pii: S0923-7534(20)42164.
PMID: 33004253